Get the Stockscreener App
1.945
0.26%
-0.005
Biomea Fusion Inc stock is traded at $1.945, with a volume of 881.81K.
It is down -0.26% in the last 24 hours and up +43.01% over the past month.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
See More
Previous Close:
$1.95
Open:
$1.97
24h Volume:
881.81K
Relative Volume:
0.64
Market Cap:
$140.98M
Revenue:
-
Net Income/Loss:
$-61.80M
P/E Ratio:
-1.2799
EPS:
-1.5197
Net Cash Flow:
$-70.37M
1W Performance:
+10.51%
1M Performance:
+43.01%
6M Performance:
+17.88%
1Y Performance:
+12.43%
1-Day Range:
$1.86
$1.99
1-Week Range:
$1.68
$1.99
52-Week Range:
$0.8719
$3.08
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.95 | 140.98M | 0 | -61.80M | -70.37M | -1.5197 |
VRTX
Vertex Pharmaceuticals Inc
|
442.07 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.79 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
843.17 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
334.47 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
317.45 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-25 | Initiated | Jefferies | Buy |
| Jun-03-25 | Resumed | Piper Sandler | Overweight |
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
BMEA.O PE Ratio & Valuation, Is BMEA.O Overvalued - Intellectia AI
COVALENT-212 study enrolls participants for icovamenib diabetes research, Biomea Fusion initiates - Traders Union
Biomea Fusion warns diabetes remains poorly controlled despite standard therapies - Traders Union
BMEA Forecast, Price Target & Analyst Ratings | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Biomea Fusion Advances Phase 2 Add-On Therapy Trial in Ozempic-Treated Diabetes - TipRanks
BMEA: Analyst Rating Maintained at Buy with Price Target Unchanged | BMEA Stock News - GuruFocus
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion (BMEA) awards 452,512 stock options to director and officer Erdtmann - Stock Titan
Biomea Fusion (BMEA) interim CEO awarded 667,477 options at $1.49 strike - Stock Titan
Icovamenib development timeline includes Phase II updates and 52-week data in 2026 - Traders Union
BMEA Technical Analysis & Stock Price Forecast - Intellectia AI
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies - The Manila Times
Biomea Fusion Announces First Patient Dosed in Newly - GlobeNewswire
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts - MarketBeat
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes - MarketBeat
Biomea Fusion reports 24 percent jump in insulin secretion in Phase 2 Icovamenib study - Traders Union
Analysts sentiment on Biomea Fusion (BMEA) remains strong amid strong diabetes trial results - MSN
Is Biomea Fusion Inc stock a good pick for beginners2026 PostEarnings & Weekly High Return Stock Forecasts - baoquankhu1.vn
Biomea Fusion (NASDAQ:BMEA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Price Target Raised to $7.00 at Citigroup - MarketBeat
HC Wainwright Comments on Biomea Fusion Q1 Earnings - MarketBeat
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth? - Yahoo Finance
Biomea Fusion prioritizes key data delivery for clinical programs - Traders Union
Biomea Fusion Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results - Insider Monkey
Biomea Fusion 2025 Financial Report - AlphaStreet
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Biomea Fusion, Inc. 2025 Annual Report: Advancing Oral Diabetes & Obesity Therapies with Innovative Small Molecule Drugs - Minichart
Aug Shorts: Can Biomea Fusion Inc ride the EV wave2026 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights - Bitget
Biomea Fusion (NASDAQ:BMEA) Issues Earnings Results - MarketBeat
Biomea 10-K: $0 Revenue, $(1.18) EPS; net loss narrows to $(61.80)M - TradingView
BMEA: Clinical progress in diabetes and obesity, reduced net loss, and strong cash position into 2027 - TradingView
Biomea Fusion (NASDAQ: BMEA) highlights icovamenib Phase II data - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Biomea Fusion (BMEA) cuts 2025 loss as icovamenib and GLP‑1 obesity programs advance - Stock Titan
Biomea Fusion targets new partnerships and investor interest at BIOEurope2026 - Traders Union
Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday - MarketBeat
If You Invested $1,000 in Biomea Fusion, Inc. (BMEA) - Stock Titan
BMEA SEC FilingsBiomea Fusion, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Street Watch: Is Biomea Fusion Inc stock overvalued or fairly priced2026 Closing Moves & Verified Momentum Stock Watchlist - baoquankhu1.vn
Heights Capital Management Inc. Reduces Stock Holdings in Biomea Fusion, Inc. $BMEA - MarketBeat
Why Is Biomea Fusion (BMEA) Stock Down 63% Today? - TradingView
Biomea Fusion, Inc. (BMEA) Presents at 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026Slideshow (NASDAQ:BMEA) 2026-03-16 - Seeking Alpha
Biomea Fusion Presents Positive Phase II COVALENT-111 Data in Type 2 Diabetes - National Today
Juan Pablo Frias presents diabetes research for Biomea Fusion at ATTD 2026 - Traders Union
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib - Benzinga
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - The Manila Times
Biomea Fusion Reports Positive 52-Week Results for Icovamenib in Type 2 Diabetes at ATTD 2026 Conference - Quiver Quantitative
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biomea Fusion Inc Stock (BMEA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hitchcock Michael J.M. | Interim CEO |
Dec 02 '25 |
Buy |
0.99 |
100,000 |
99,180 |
115,000 |
| Erdtmann Rainer M | See Remarks |
Nov 28 '25 |
Buy |
1.10 |
40,000 |
44,052 |
683,027 |
| Erdtmann Rainer M | See Remarks |
Dec 01 '25 |
Buy |
1.05 |
10,000 |
10,500 |
693,027 |
2.68%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):